Navigation Links
UPM Signs Joint Development Agreement with Renmatix in Biochemicals

HELSINKI, June 11, 2013 /PRNewswire/ -- UPM (OMX: UPM1V) and Renmatix, Inc., have entered into a non-exclusive joint development agreement (JDA) in the area of biochemicals. Under terms of the JDA both companies will further develop Renmatix's water-based Plantrose™ process to convert woody biomass into low-cost sugar intermediates for subsequent downstream processing into biochemicals. Offering cost-competitive bio-alternatives for select petrochemicals on an industrial scale is the long term goal of this initiative.

"We are very excited about this truly collaborative endeavor. It combines UPM's core competencies in sustainable sourcing and efficient industrial processing of wood, with Renmatix's unique conversion technology," noted Michael Duetsch, Director of Biochemicals, at UPM. "Access to second generation, lignocellulosic, sugars through a process that uses almost no consumables is a crucial factor in Plantrose technology's attractiveness."

The Plantrose process employs water at very high temperatures and pressures to breakdown biomass through supercritical hydrolysis. Under such conditions water can act as both a powerful solvent and catalyst, creating rapid reactions.

"We believe this pioneering approach leads to real cost advantages over conventional methods. Our growing relationship with UPM gives Renmatix an opportunity to support them expanding the Biofore story," commented Mike Hamilton, CEO of Renmatix. "Renmatix, as a U.S. based technology provider, takes great pride in working with global companies across the emerging bio-value chains. It reinforces the demand that exists for licensing Plantrose technology as the bridge between sustainable sources of upstream biomass, and downstream manufacturing of biochemicals and fuels."


SOURCE Renmatix
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Elsevier Signs Strategic Collaboration Agreement with Peoples Medical Publishing House, China
2. Alexandrias 499 Illinois Street in Mission Bay, San Francisco, Signs Anchor 97,700 Rentable Square Foot Lease with Leading Mid-Cap Life Science Company
3. Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team
4. Phosphagenics Signs Research Agreement with the Agricultural Research Service
5. Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement with Bristol-Myers Squibb
6. Vestiage Signs Buyside Engagement Agreement with CJK Securities
7. Vertilon Signs Crisel Instruments as its Distributor in Italy
8. Bausch + Lomb Signs Exclusive License Agreement with Paragon BioTeck for Phenylephrine
9. Entertainment Agency and Speaker Bureau Mark Sonder Productions Signs the Health & Wellness Shaman, Robert Cohen, PhD, LPC, DCEP for Meetings and Events Worldwide
10. Samsung Thales signs Development Agreement with Novelda
11. Eddie Leong Signs on as Advisory Board Member and Compliance Officer for Grace Century, International Research and Private Equity Consultant
Post Your Comments:
(Date:10/9/2015)...  Pulmatrix, Inc., (NASDAQ: PULM ) will be webcasting ... th Annual BIO Investor Forum on Tuesday, ... --> th Annual BIO Investor Forum ... pm EDT). --> Pulmatrix will be presenting ... on Thursday, October 15, 2015 at 8:30 am EDT. Additionally, ...
(Date:10/8/2015)... SAN DIEGO , Oct. 8, 2015 /PRNewswire/ ... oncology company developing new treatments for cancer and ... Chief Executive Officer, will be presenting at the ... Las Vegas :Event:Aegis Capital Corporation 2015 ... PDTLocation:Brahms 2 room, The Encore @ The Wynn ...
(Date:10/8/2015)... 2015 .   ... Goldman Small Cap Research, a stock market ... microcap sectors, announced today that it has published ... Inc. (OTCQB - PMCB), a publicly traded, clinical ... treatments for cancer and diabetes. To view the ...
(Date:10/8/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... the development of autologous cell therapies, today announced its schedule ... place in the month of October: Stem ... RepliCel will be presenting at the annual Partnering Forum, ... to be held October 7-9 in La ...
Breaking Biology Technology:
... sole U.S. supplier of 3M electrosurgical grounding pads ... ... Industries, Inc. and,3M Health Care announce an exclusive license and supply ... agreement,Medline has acquired the exclusive license and sales rights in the ...
... Eastern Time Today, GAITHERSBURG, Md., March 6 ... and corporate progress for,the full year ended December 31, ... further demonstrated that Iomai,s,vaccine and immunostimulant patches can be ... chief executive officer,of Iomai. "This lays the foundation for ...
... (Pink Sheets: VXGN), a biopharmaceutical company, today reported its,year ... a view to,ensuring that stockholders have the most current ... with Raven biotechnologies,inc. VaxGen,s Board of Directors has set ... of Stockholders to vote on the proposed merger., ...
Cached Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  The global glucose monitoring device ... 2015. So says a new report on the industry from ... segment dominate the market, followed by continuous glucose monitoring and ... on the market for these products in its latest report, ... , ...
(Date:9/28/2015)... , Sept. 28, 2015 ... today that its expedited traveler service is ... platform transforms travel, bringing a frictionless experience, ... members. "CLEAR offers our travelers ... customer service," said Jim Smith , ...
(Date:9/28/2015)... , September 28, 2015 ... Component (Hardware & Software), Product (Scanner & Others), Application ... & Defense, & Others) & Geography Global - Forecast ... expected to reach USD 3627.90 Million by 2020, at ... Browse 65 market data T ables ...
Breaking Biology News(10 mins):
... and Nanosystems Research (IBN), Austrian Academy of Sciences ... of Technology, Cambridge, USA report the study of ... Designer Lipid-Like Peptide Surfactants” in the May 30th ... Their findings not only help us to ...
... a chronic and progressive lung disorder from which most patients ... by the insidious onset of dyspnea or cough and usually ... coworkers present in an article published in the online, open-access ... that a subset of IPF patients has a short duration ...
... chronic lung disease typically characterized by the slow but ... patients live about five years after diagnosis. However, according ... online journal PLoS ONE, a subset of patients with ... progression to complete pulmonary failure and death without a ...
Cached Biology News: